Vista Pharmaceuticals Ltd does manufacturing and selling of Pharmaceutical, medical and veterinary preparations. The company also sells products to its related companies engaged in the manufacture of formulationsBusiness Overview: Company offers over-the-counter & prescription generic drug products consisting of tablets, capsules, and liquids covering various therapeutic categories. It formulates, registers,...
Vista Pharmaceuticals' Board has approved the allotment of 1.02 Cr fully convertible warrants to non-promoters on a preferential basis. Each warrant is priced at ₹12, making the total consideration ₹12.30 Cr. The company has already received ₹3.07 Cr, representing 25% of the issue price. This allotment is a portion of...
Vista Pharmaceuticals has confirmed adherence to regulations concerning the dematerialization of shares. The company, via its Registrar and Transfer Agent, certified that all securities received for conversion from physical to electronic form were duly processed. This includes their verification, cancellation of physical certificates, and updating of records with the depository's...
Vista Pharmaceuticals Limited has submitted its Annual Secretarial Compliance Report by M/s. Aakanksha Dubey & Co., confirming overall adherence to applicable statutory provisions and corporate governance practices for the year ended 31.03.2025. The company addressed previous regulatory observations and paid fines related to delayed appointment of compliance officers, company secretary,...
Vista Pharmaceuticals has announced a board meeting to discuss compliance with SEBI regulations, specifically regarding the dematerialization of securities for the quarter ended March 31, 2025. The company confirms that securities received for dematerialization were correctly processed, mutilated, and cancelled, with the depository's name updated in their records. This compliance...
